A supplement for sequential adjuvant oncological treatment, comprising a Kit (1) of substances suitable to produce ROS with the aim of selective biological damage for cancer cells, a Kit (2) of substances having functionalities of differentiation and of apoptosis of the neoplastic cells that survived the biological damage induced by the treatment with aforesaid Kit (1), and a Kit (3) of substances that perform the function of metastatic blockage of the neoplastic cells that survived the treatment with the aforesaid Kit (2). In relation to known radio and chemotherapy treatments in the cancer field, the supplement of the invention allows an increase in the effectiveness of the therapy, significantly improving the therapeutic results obtained with or without conventional therapies and the quality of life of the patient, with an increase in survival. The administration of this supplement, while keeping the disease under control, would prevent massive tumour lysis syndrome, often resulting from chemo/radiotherapy, leading to severe functional failure of excretory organs (kidneys/liver) and cardiac failure, causing the death of the patient. Obtaining cancer as a stable chronic disease under control would prevent the lethal consequences caused by massive neoplastic destruction, increasing survival with excellent quality of life.La présente invention concerne un complément pour un traitement oncologique à adjuvant séquentiel, comprenant un kit (1) de substances adaptées à produire des ROS dans le but de causer un dommage biologique sélectif à des cellules cancéreuses, un kit (2) de substances présentant des fonctionnalités de différentiation et dapoptose des cellules néoplasiques qui ont survécu aux dommages biologiques causés par le traitement par le kit précité (1), et un kit (3) de substances qui remplissent la fonction de blocage métastatique des cellules néoplasiques qui ont survécu au traitement par le kit précité (2). Par rapport à des traitements connus de radiothé
